secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edwards Lifesciences Corp (EW)
CIK:        0001099800
Form:       8-K
Filed at:   2023-07-26T23:59:59+00:00
Accession:  0001099800-23-000032
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edwards Q2 sales $1.53B (+11% YoY); adj EPS $0.66; raises FY23 guidance
-----------------------------------------------------------------------

- Q2 sales $1.53B (+11%/+12% constant currency); GAAP EPS $0.50 (incl. IP charge), adjusted EPS $0.66.
- TAVR sales $992M (+9%/+10% constant currency); TMTT $48M; Surgical $256M; Critical Care $235M.
- Raised FY2023 sales guide to $5.9-$6.1B (prior $5.6-$6.0B), constant currency growth 10-13%.
- Adjusted EPS guide raised to $2.50-$2.60 (prior $2.48-$2.60); Q3 guide $1.44-$1.52B sales, $0.55-$0.61 adj EPS.
- Adjusted gross margin 77.7% (vs 80.5% YoY); $300M IP payment; cash $1.5B, debt $600M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1099800/000109980023000032/0001099800-23-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1099800/000109980023000032/ew-20230726.htm
  HTML page:      https://secwatch.observer/filing/0001099800-23-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer